ALK

Read more
Jens Bager's photo - CEO of ALK

CEO

Jens Bager

CEO Approval Rating

89/100

Founded:

06/1923

Status:

PublicIndependent CompanyNasdaq OMX NordicALK B

Annual Revenue
$497M
Employees
2,300
Sector

- -
Headquarters

ALK TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

ALK's company profile
Jens Bager's photo - CEO of ALK

Jens Bager

CEO

89/100
2,300
$0
$497M
View Profile
1
ALK's Competitor - Stallergenes logo
Christian Chavy's photo - CEO of Stallergenes

Christian Chavy

CEO

70/100
1,024
- -
$186.3M
View Profile
2
ALK's Competitor - Allergy Therapeutics Plc logo
CEO Avatar

CEO

- -
- -
View Profile
3
ALK's Competitor - Circassia Pharmaceuticals logo
Steve Harris's photo - CEO of Circassia Pharmaceuticals

Steve Harris

CEO

51/100
350
- -
$81.8M
View Profile
4
ALK's Competitor - Trusted Tablets logo
CEO Avatar

CEO

- -
19
- -
$1.2M
View Profile
5
ALK's Competitor - HAL Allergy logo
Harry Flore's photo - CEO of HAL Allergy

Harry Flore

CEO

70/100
505
- -
$15M
View Profile

Missing a competitor? Contribute!

Stallergenes is seen as one of ALK's top competitors. Stallergenes's headquarters is in Tocqueville Antony, Other, and was founded in 1962. Stallergenes competes in the Health Care Services industry. Stallergenes generates 37% of ALK's revenue.

Allergy Therapeutics Plc is one of ALK's top rivals. Allergy Therapeutics Plc was founded in null, and its headquarters is in , . Allergy Therapeutics Plc competes in the field. Allergy Therapeutics Plc has NaN fewer employees than ALK.

Circassia Pharmaceuticals is ALK's #3 rival. Circassia Pharmaceuticals is a Public company that was founded in 2006 in Oxford, England. Circassia Pharmaceuticals operates in the Biotechnology industry. Compared to ALK, Circassia Pharmaceuticals has 1,950 fewer employees.

ALK Quarterly and Annual Revenue

Coming soon for ALK!

Annual Revenue

$497M

ALK's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 156.3M.

ALK Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
OTIPRIO

Jun 2021

Source »
undisclosed
-
Crystal Laboratory, LLC

Dec 2016

Source »
undisclosed
Crystal Laboratory produces and supplies pollens and powdered allergens.
Allergy Laboratories, Inc.

Dec 2016

Source »
undisclosed
Allergy Labs is a manufacturer of biological extracts for diagnostic testing and therapeutic treatment of allergy.
Bio-Medical Services, Inc.

Feb 2014

Source »
undisclosed
-

These are all the companies that ALK has acquired. ALK has acquired 4 companies and its latest acquisition was OTIPRIO in Jun 2021.

ALK Funding History

No recent funding data found related to ALK

ALK Investments

No recent investments found related to ALK

ALK News

June 3, 2021BioSpace

ALK Acquires OTIPRIO (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients

ALK (ALKB:DC / OMX:ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focu... See more »
May 5, 2021Markets Insider

Three-month interim report (Q1) 2021

ALK reports 9% sales growth in Q1 fuelled by better than expected tablet growth of 32% (unaudited)The... See more »
April 19, 2021The Pharma Letter

ALK gains US pediatric approval for its ragweed SLIT-tablet

The US Food and Drug Administration has expanded the use of ALK Abello's ragweed sublingual allergy..... See more »
February 24, 2021MarketScreener

Report on transactions with ALK-Abell A/S B-shares and associated securities by managerial staff

(marketscreener.com) ALK reports the following transactions: 1. Details of the person discharging man... See more »
February 10, 2021The Pharma Letter

ALK Abello shares jump as financial results show continued growth

Danish allergy immunotherapy specialist ALK Abello was trading 8% higher during Wednesday afternoon,.... See more »
February 10, 2021Markets Insider

ALK releases 2020 annual report

ALK ends 2020 with Q4 organic growth of 16% leading to full-year revenue growth of 8%Results in line ... See more »
December 22, 2020The Pharma Letter

BRIEF-Ragwitek approved in Canada

Danish immunology specialist ALK has won Canadian approval for its once-daily allergy treatment Ragwi... See more »

ALK Press Releases

March 19, 2021StreetInsider

Annual General Meeting in ALK-Abell A/S held on 18 March 2021

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 18 Marc... See more »
February 23, 2021GlobeNewswire

Annual General Meeting in ALK-Abell A/S on 18 March 2021

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): The Annual General Meeting of ALK-Abelló A/S will be held... See more »
December 17, 2020GlobeNewswire

ALK - Finanskalender for regnskabsret 2021

Finanskalender 2021 for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF):... See more »
November 11, 2020GlobeNewswire

Nine-month interim report (Q3) 2020

Bemærk venligst, at rapporten udelukkende findes på engelsk.... See more »
November 6, 2020GlobeNewswire

Two new members of ALK's Board of Directors

The Board of Directors at ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) is to nominate Gitte Pugholm Aab... See more »
November 5, 2020GlobalNewswire

Release date of nine-month interim report (Q3) 2020 for ALK and audio cast

On Wednesday, 11 November 2020, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its nine-month in... See more »
October 5, 2020Cision Canada

ALK Announces that ITULATEK Sublingual Allergy Immunotherapy (SLIT)-Tablet for the Treatment of Tree Pollen Allergy is Now Available in Canada

/CNW/ -- ALK, a global, research-driven pharmaceutical company that focuses on the prevention, diagno... See more »

Social Media

ALK Headquarters

Bøge Allé 6-8

Hørsholm, Other2970

45-4574-7576

Driving Directions »

Trending Companies

ALK Summary

ABOUT

Overview

ALK is engaged in the research and development of allergy immunotherapy products for the prevention and treatment of allergy. ALK was founded in 06/1923. ALK's headquarters is located in Hørsholm, Other, DK 2970. ALK's CEO, Jens Bager, currently has ...

CEO

ALK's CEO, Jens Bager, currently has an approval rating of 89%. ALK's primary competitors are Stallergenes, Allergy Therapeutics Plc & Circassia Pharmaceuticals.

Frequently Asked Questions about ALK

  1. When was ALK founded?

    ALK was founded in 06/1923
  2. Who is ALK's CEO?

    ALK's CEO is Jens Bager
  3. How much revenue does ALK generate?

    ALK generates $497M in revenue
  4. How much funding does ALK have?

    ALK has historically raised $0 in funding
  1. Where is ALK's headquarters?

    ALK's headquarters is in Hørsholm Other, DK
  2. How many employees does ALK have?

    ALK has 2,300 employees
  3. Who are ALK's competitors?

    ALK's top competitors are Stallergenes, Allergy Therapeutics Plc, Circassia Pharmaceuticals